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Monoclonal antibodies were  raised that specifically 
recognize  the NH2-terminal neoepitope sequence pres- 
ent in link protein cleavage products derived from 
stromelysin-degraded proteoglycan aggregate. Com- 
petitive enzyme-linked immunosorbent assay, using 
synthetic peptides as inhibitors, showed that one of 
these antibodies (CH-3) required, for antibody recog- 
nition, the free N&-terminal amino acid isoleucine 
(residue 17 of the intact protein) in the sequence NH2- 
IQAENG at the stromelysin cleavage  site of link pro- 
tein 3. Human proteoglycan aggregate was digested 
with recombinant human stromelysin,  bovine chymo- 
trypsin,  bovine  trypsin, and porcine elastase, and their 
respective  link protein degradation products were 
tested for immunoreactivity with antibody CH-3. Only 
stromelysin- and chymotrypsin-generated link protein 
3 were recognized by antibody CH-3. Both of these 
enzymes  generate  link protein NH2 termini with  the 
sequence “IQAENG. . .; hence  these  studies indicated 
that monoclonal antibody CH-3 recognized this neoepi- 
tope sequence in only  specific  proteolytically modified 
link protein molecules. Since the occurrence of link 
protein 3 increases  with  aging,  the incidence of CH-3 
epitope in proteoglycans isolated from human knee 
articular cartilage of individuals of  different ages  was 
investigated. The prevalence of CH-3 epitope was 
found to be highest in newborn and adolescent articu- 
lar  cartilage samples. However,  little CH-3 epitope was 
detected in older adult cartilage, although considerably 
more link protein 3 was present in  these samples. These 
results suggest that additional proteolytic agents  are 
responsible for the increased occurrence of  link protein 
degradation products with  aging. 
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Mechanisms of proteoglycan  breakdown in connective tis- 
sues  are complex and involve multiple  agents  and  pathways 
(1). This  is  indicated by several  studies  examining  the  turn- 
over of matrix macromolecules in  both  articular cartilage and 
intervertebral disc (2-6). Recently,  amino acid  sequence 
analysis of cartilage proteoglycan  breakdown products (4-6) 
has  contributed  to  the  identification of putative  sites of ca- 
tabolism  within  these macromolecules. The occurrence of the 
different sequences at  these cleavage sites  indicates  that sev- 
eral  different  agents  must be involved in proteoglycan turn- 
over. At present the identity and the source of the agents 
responsible  for this  degradation  and  the  extent  to which each 
agent  is  contributing  to  the  turnover of these molecules have 
not been  definitively established. However,  since many of the 
proteolytic cleavage sites  in proteoglycan are now known, we 
hypothesized that  it  should be possible to use  immunological 
procedures  to  both  identify  and  quantitate  the occurrence of 
an  agent-specific cleavage site  in  these molecules. It  has been 
demonstrated previously in  the case of fibrinogen (7)  that  on 
cleavage of a protein,  the new NH2  and COOH termini  pro- 
duced have  different  properties,  in  terms of antibody recog- 
nition,  than  the  same s quences present  in  the  intact  protein. 
These  findings suggest that  it  should be  possible, therefore, 
to produce antibodies specific for the  products of proteoglycan 
aggregate components that have been cleaved by specific 
proteinases. Proteinases can cleave all susceptible peptide 
bonds  without  bias for the  protein  in which they occur. Thus, 
in principle, any  matrix  protein may be used as a marker for 
proteinase  action. However, in  practice,  it is necessary that 
the  protein be  cleaved  by physiologically relevant  proteinases, 
and  at  least  one recognizable degradation product must re- 
main localized within  the tissue. Link  protein  from cartilage 
proteoglycan  aggregate satisfies  these  criteria (8). 
Link  protein  (LP)’  is a small globular protein which stabi- 
lizes the  interaction between the  cartilage proteoglycan mon- 
omer (aggrecan) and hyaluronan (9, 10). This interaction 
results  in  the  formation of the large proteoglycan  aggregates 
that endow cartilage  with  its  property of resistance  to 
compression under load (11, 12).  Link  protein isolated from 
human  articular  cartilage  can be separated  into  three com- 
ponents  with  estimated molecular masses of 48, 44, and 41 
kDa, which are  referred  to  as  LP1,  LP2,  and  LP3, respectively 
(13-15). Peptide  mapping  and  amino acid  sequence analysis 
indicated  that  the  different  forms of link  protein  are derived 
from  the  same  protein core (16-19). The difference in electro- 
phoretic  migration of LP1  and  LP2  has been  shown to be due 
to  the  differential  substitution of N-linked oligosaccharides 
on  the two different  link  protein  components (15-17,19, 20). 
Nguyen et al. (18) have demonstrated  that  human  LP1  and 
LP2 differ only by the  presence of an  N-linked oligosaccharide 
at residue 6 in  LP1.  LP3 is a proteolytic cleavage product of 
either  LP1 or LP2, which appears  to have similar  functional 
properties  to  those of the  intact molecule (8, 15).  The NH,- 
terminal region of LP1  and  LP2, between  residues  10 and 30, 
appears  to be extremely susceptible to  proteolytic  attack,  and 
The abbreviations used are: LP, link protein; BA, p-alanine; 
ELISA, enzyme-linked immunosorbent assay; EIA, enzyme immu- 
noassay; BSA, bovine serum  albumin;  SDS, sodium dodecyl sulfate; 
PAGE, polyacrylamide gel electrophoresis; PBS, phosphate-buffered 
saline. 
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the cleavage positions for many  proteinases  have been deter- 
mined (8). When LP3 preparations isolated  from normal  and 
diseased human  articular  cartilage were analyzed, three  dis- 
tinct NH2 termini were found. By comparison with the in 
vitro cleavage data,  the  proteinases of physiological relevance 
thought to be responsible  for generating these new NH2 
termini were postulated to be stromelysin, cathepsin G, or 
cathepsin B (8). Human  cartilage LP3 is  therefore  present  as 
a family of molecules, the  identity of which depends  on  the 
proteinase responsible  for its  generation.  Since  the  generation 
of each LP3 produces  a unique NH, terminus, we propose the 
nomenclature LP3(n) for each defined LP3, where n repre- 
sents the sequence position of the NH2 terminus of the 
molecule relative to that in the native protein. Thus, LP3 
generated by the  action of stromelysin  is  denoted  as LP3(17). 
In  this  paper we describe a novel approach,  using  mono- 
clonal antibody technology, to identify proteolytic agents 
responsible  for the  degradation of matrix macromolecules, in 
normal  turnover  and  in disease, by preparing  antibodies  spe- 
cific for the cleavage sites produced by different  proteinases 
in  matrix molecules. As an example, this  study was directed 
toward examining the role that stromelysin plays in the 
degradation of link  protein  during  cartilage proteoglycan ca- 
tabolism. 
EXPERIMENTAL  PROCEDURES 
Materials-Pristane (2,6,10,14-tetramethylpentadecane) was ob- 
tained from Aldrich and  1,lO-phenanthroline from Mallinckrodt 
Chemical Works. Titertek EIA plates were purchased from Flow 
Laboratories. Alkaline phosphatase-conjugated  rabbit  anti-mouse 
Fab,, used in  ELISA was obtained from Southern Biotechnology  Inc., 
Birmingham, AL. Alkaline phosphatase-conjugated second antibody 
and  substrate used in  the  Western  blot  analysis were obtained  from 
Promega as the Protoblot Western blot AP system (catalog no. 
W3920). Nitrocellulose (0.2-pm pore size) was obtained from Bio- 
Had  and polyvinylidene  difluoride membrane  (Immobilon)  from Mil- 
lipore. Human  recombinant  prostromelysin was  a generous gift from 
Dr. Gillian Murphy,  Strangeways  Research  Laboratories, Cambridge, 
LJ.K. Bovine chymotrypsin (tosyllysine chloromethyl  ketone-treated), 
bovine trypsin  (tosylphenylalanine  chloromethyl  ketone-treated),  and 
porcine pancreatic elastase were all purchased from Sigma. Mono- 
clonal  antibody 8-A-4 was prepared  as  ascitic fluid and also purchased 
from the Developmental Studies Hybridoma Bank (University of 
Iowa, Iowa City, IA).  This  antibody recognizes a linear amino acid 
sequence epitope  in  the  paired  tandem  repeat  domains of li k proteins 
isolated from many  animal species (16). All other chemical reagents 
used that are not specifically mentioned above were of analytical 
grade  and  obtained from either Sigma or  Fisher Scientific. 
Preparation  ofAntigensfor  Immunization and Screening-Peptides 
were synthesized, a t  a 0.5-mmol scale using standard Fmoc (9-flu- 
orenylmethoxycarbonyl)  chemistry,  on  an Applied  Biosystems model 
431A solid phase  peptide  synthesizer.  Crude  peptides were purified 
by reverse phase chromatography (Prep-10 Aquapore C8 column, 
Applied Biosystems) using an acetonitrile gradient in 0.1% trifluo- 
roacetic acid. Peptides  synthesized were IQAENGGC, IQAENG(BA)C, 
Ac-IQAENG(BA)C, IHIQAENGGC, HIQAENGGC, QAENG(BA)C, 
AENGPHGGC,  and  DHLSDNYTGGC.  Most  peptides  contained a 
COOH-terminal spacer amino acid, glycine, followed by a cysteine 
residue  that was  used as  the coupling site for preparation of peptide- 
protein conjugates. In some peptides used to  probe  antibody specific- 
ity, @-alanine (@A) was used as a substitute for the glycine spacer 
residue. 
The bifunctional reagent, N-hydroxysuccinimidylbromoacetate, 
was  synthesized  as described by Bernatowicz and  Matsueda (21). For 
coupling, 0.2 ml of an  65 mg/ml solution of this  bifunctional  reagent 
in dimethylformamide  was added, dropwise,  with continuous  stirring 
to  2.25 ml of ovalbumin (22 mg/ml) dissolved in 0.1 M potassium 
phosphate,  pH 7.5, containing 1 mM EDTA a t  4  "C. The  mixture was 
then allowed to  equilibrate  to room temperature over a 30-min  time 
period.  The  activated  ovalbumin was separated from unreacted re- 
agents by gel filtration using a Sephadex  G-25  column  (25 X 1.5 cm) 
eluted with the  EDTA-phosphate buffer described above. The  syn- 
thetic  peptide  to be coupled to  the  carrier  protein was dissolved in 
water (0.4 ml) a t  a concentration of 6 mM and  added  to 0.4 ml of the 
Sephadex G-25 eluate peak fraction containing the activated oval- 
bumin.  The  mixture was initially  shaken  gently  under nitrogen for 2 
h at  room temperature, followed by continued  incubation  overnight 
at  4  "C. Unreacted  bromoacetate groups were blocked by the  addition 
of mercaptoethanol(1 ~ l ) ,  and  the  solution was dialyzed exhaustively 
against  PBS.  The success of the coupling reaction was determined by 
observation of a  decrease in  electrophoretic mobility of the  peptide- 
ovalbumin conjugate, on  SDS-PAGE, relative to a cysteine-ovalbu- 
min conjugate prepared in the same manner. The identity of the 
peptide  on  the conjugate was confirmed by peptide sequencing, fol- 
lowing SDS-PAGE  and  electroblotting  onto a  polyvinylidene  difluo- 
ride membrane  (22). 
Immunization and Fusion-The antigen used for immunization 
was a peptide-ovalbumin conjugate, consisting of the  synthetic pep- 
tide  IQAENGGC coupled to  the  carrier  protein. A  single 4-6-week- 
old  female  BALB/c mouse was  immunized with the ovalbumin- 
peptide conjugate. Procedures for immunization, cell fusion, and 
hybridoma selection were as described by Caterson et al. (23, 24). 
After 10-14 days  in  culture,  the wells were visually inspected for the 
presence of viable  hybridomas.  Aliquots from  each of the hybridoma- 
containing wells were tested in ELISA for the presence of mouse 
immunoglobulin  with  specificity directed  against  the original immu- 
nizing antigen.  These  hybridoma  supernatants were also tested for 
antibody activity against ovalbumin-peptide conjugates containing 
an unrelated peptide sequence, in order to distinguish hybridomas 
that produced antibodies recognizing the  synthetic  peptide from those 
recognizing epitopes  in  either  the coupling region of the conjugate or 
the  carrier  protein.  Hybridomas  from wells producing antibody di- 
rected against epitopes in the synthetic peptide component of the 
ovalbumin-peptide conjugate were then  expanded  and subcloned by 
limiting  dilution.  Media from the  resultant monoclonal  hybridomas 
were retested in ELISA for their production of immunoglobulin 
directed  against  the original antigen,  then  expanded in cell culture, 
and used for ascites  production. Ascites were produced by the  intra- 
peritoneal injection of  10fi-lO' cells into female retired breeder BALB/ 
c mice that had been previously primed with an intraperitoneal 
injection of 0.5 ml of Pristane 1-2 days earlier. Ascitic fluid was 
usually harvested 2-3 weeks after  the  hybridoma  injection  and  stored 
in  the presence of 0.02%  NaN3. The  antibody isotype was determined 
using an Isotype screening  kit supplied by Southern Biotechnology 
Inc., Birmingham, AL. 
ELISA Screening Procedures-Antigens were dissolved in PBS- 
azide (0.14 M NaC1, 0.01 M sodium phosphate, pH 7.2, containing 
0.02% NaN3) and coated a t  a concentration of 3 pg/ml on 96-well 
Titertek EIA plates by passive absorption  either  overnight a t  4 "C or 
for 3 h a t  37 'C. The  plates were washed with PBS-azide,  and  the 
unreacted  sites were blocked by the  addition of EIA buffer  (1% BSA 
in  PBS-azide; 200 pl/well) followed by incubation for 1 h at  37 "C. 
The  plates were then washed three  times with PBS-azide,  and 200 p1 
of each hybridoma culture supernatant was added to appropriate 
wells of the  EIA  plates  and  incubated for 1 h a t  37 "C. The  plates 
were washed  four times with PBS-azide, followed by the  addition of 
200 pl of a 1:500 dilution of enzyme-linked  second  antibody  solution 
(alkaline  phosphatase-conjugated  rabbit  anti-mouse  Fabd  and  incu- 
bation for 1 h a t  37 "C. The  plates were washed five times with Tris- 
saline buffer (0.2 M NaCI, 0.05 M Tris-HC1, pH 7.4) and  then 
incubated a t  37 "C with alkaline phosphatase substrate (p-nitro- 
phenyl  phosphate, 1 mg/ml in 0.126 mM MgC12, 0.86 M diethanola- 
mine, pH 9.8) until  optimal color development occurred  (usually 30- 
90 min).  The color was quantified by measuring the absorption at 
405 nm  on a Titertek  Multiskan (Flow Laboratories). 
ELISA Znhibition Assays-The immunizing peptide antigen was 
dissolved in  PBS-azide  and  coated  onto EIA plates a t  3 pg/ml  (200 
pl/well), then blocked in  EIA buffer, as described above. A panel of 
peptides,  all a t  1 mg/ml, was  serially diluted  in EIA  buffer (concen- 
tration range from 0 up to 30 pg/100 pl) and incubated a t  room 
temperature for 1 h with monoclonal antibody  CH-3  (final  dilution 
of 1:10,000 in 200 pl) prior to incubation for 1 h a t  37 "C in the 
appropriate well of the  antigen-coated  and blocked EIA plate. The 
plates were washed and incubated with secondary antibody as de- 
scribed above in the direct ELISA. Substrate was then added, and 
the  plates were incubated a t  37 "C until  the well that  contained no 
competing  antigen  (0 pg/ml) gave an  absorbance reading of approxi- 
mately 1.0 at 405 nm.  This reading was taken  as  100%. 
Proteinase Digestion of Cartilage Proteoglycan Aggregate-Proteo- 
glycan aggregate  isolated from  normal  human knee articular  cartilage 
was prepared by associative CsCl equilibrium density  gradient  cen- 
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trifugation  (13).  The  proteoglycan  aggregate  fraction (Al) '  was  sub- 
jected  to  proteolytic  digestion  with  either  chymotrypsin,  trypsin, or 
1)ancreatic elastase. Digestion mixtures (0.1 ml) contained 2 mg/ml 
proteoglycan aggregate in 0.1 M Tris-HCI,  pH 7.5, and 20 pg/ml of 
either of the  three  proteinases  listed  above.  Following  incuhation  at 
37 "C for  4 h, the  enzymes were inactivated by addition of an  equal 
volume of SIX-PAGE  sample buffer  (without  mercaptoethanol)  and 
heated  immediately in a boiling  water  bath  for 3 min. The  proteogly- 
can aggregate  was also suhjected  to  digestion  with  recombinant pros- 
t romelysin,  which  had  been  preactivated by p-aminophenyl  mercuric 
acetate  treatment  (25).  Incubations  contained 1 mg/ml  proteoglycan 
aggregate  in 0.1 M Tris-HCI,  pH 7.5, containing 10 mM CaCI,! and  10 
pg/ml  stromelysin  and  were allowed to proceed a t  37  "C  for 24 h and 
then terminated as above. Link proteins were separated by SDS- 
I'AGE, electroblotted  onto  nitrocellulose,  and  immunolocalized  with 
monoclonal  antibodies  using  procedures  described below. 
/solation and Anal.vsis of Cartilage  Matrix  Proteins-Macroscopi- 
cally  normal  human  articular  cartilage  was  obtained  from  the  distal 
I'emur at  autopsy,  within 16 h of death,  from  donors  aged 6 weeks, 2 
years, 10  years, 23 years,  and  58  years,  respectively. The  tissue  was 
finely diced and  extracted  with  4 M guanidinium  chloride-containing 
proteinase inhibitors (26), and the protein-rich components of the 
cartilage  extracts  were  isolated by direct  dissociative  CsCl  equilibrium 
density  gradient  centrifugation  using a starting  density of  1.50 g/ml 
( 14).  After  centrifugation,  the  tubes  were  divided  into  three  fractions 
(I>l-DX),'which  were then dialyzed and freeze-dried.  Cartilage  matrix 
proteins  in  the low buoyant  density  D3  fraction  were  dissolved at  2 
mg/ml in 4 M guanidinium chloride, 0.1 M sodium acetate, pH 6.3, 
and  then dialyzed at  room temperature  against  two  changes of 0.125 
M Tris-HCI,  pH 6.8, containing 0.1% SDS.  Samples  (50  pg/well) were 
suhjected  to  SDS-PAGE, followed by electroblotting  onto  nitrocellu- 
lose memhranes. Link proteins were immunolocalized with mono- 
clonal  antibodies  8-A-4  and  CH-3  using  procedures  described low. 
SI~.S-I'ol.vac~lamide Gel Electrophoresis and 1mmunoblottin~- 
Samples  containing  native  and  degraded  link  protein  were  electro- 
phoresed  on 10%; polyacrylamide  slab gels in SDS using  procedures 
described by Laemmli (27). After electrophoresis, the fractionated 
proteins  were  electrophoretically  transferred  to  nitrocellulose  mem- 
Iwanes. The transfer sheet was incubated in blocking solution (3% 
(w/v) hovine  serum  albumin  in  PBS-azide)  overnight,  then  incubated 
with  a 1:2000 dilution of monoclonal  antibody 8A4 or a 1:100 dilution 
ofCH8 in THST (0.05% Tween 20 in  0.15 M NaCI, 0.01 M Tris-HCI, 
pH 8.0)  for 30 min at  37 "C. After 3 washes  with TRST buffer, the 
nit.rocellulose  sheets  were  incubated for 30 min a t  37  "C  with a 1:7500 
dilution of an alkaline phosphatase-conjugated rabbit anti-mouse 
second  antibody in TRST buffer. The nitrocellulose  was then  thor- 
oughly washed in TBST buffer and  then washed  in  one  change of 
dkaline phosphatase buffer (100 mM NaCI, 5 mM MgCI?, 100 mM 
' lh-HCI,   pH 9.5) before  addition of freshly  prepared  alkaline  phos- 
phatase  substrate  solution (66 pl of nitro  blue  tetrazolium  (50  mg/ml 
in 70% dimethylformamide)  and  33 pl of 5-bromo-4-chloro-3-indoyl 
phosphate (50 mg/ml in dimethylformamide) in 10 ml of alkaline 
phosphatase  buffer).  In  general,  the  immunoblots  were  incubated  for 
10-30 min at  room temperature  to  achieve  optimum  color  develop- 
ment. 
RESULTS 
Characterization of a Monoclonal Antibody Specific for 
LP3(17)-Mice were immunized with a synthetic  peptide  con- 
jugate containing the first 6 residues of the NH2-terminal 
neoepitope  produced from cleavage of native link protein by 
stromelysin.  Preliminary  screening of hybridoma supernatant 
specificity in direct  ELISA identified  six  clones (denoted  CH- 
3 to CH-8,  respectively) that recognized the immunizing an- 
tigen. These  antibodies showed no reactivity  with unrelated 
synthetic peptide conjugates nor with the carrier protein. 
Hybridoma clone CH-3 showed the  strongest reactivity in  the 
preliminary screening and  thus was processed further.  The 
CH-3 hybridoma cell line  was  cloned by limiting  dilution,  and 
its antibody  isotype determined  as being an IgGl heavy chain 
and K light chain. 
The reactivity of monoclonal antibody  CH-3  against a  series 
' A1 and  Dl-D3 as used in  Ref. 12. 
of unconjugated  peptides, related  to  the immunizing  antigen 
but having modifications a t  both  the NH,- and  COOH-ter- 
minal  amino acids, was tested in  competitive  ELISA (Fig. 1). 
These analyses showed that the unconjugated immunizing 
peptide  and  the  same  peptide with  a modified COOH-terminal 
amino acid  sequence both gave 50% of the maximum  absorb- 
ance a t  a concentration of 25 pg/ml peptide (Fig. 1, open 
symbols). Acetylation of the peptide resulted in a marked 
reduction in inhibition, while removal of the NH,-terminal 
amino acid (isoleucine) resulted in a complete loss of this 
inhibition. Similarly,  NH,-terminal addition of further resi- 
dues from the link protein sequence (Fig. 2 A )  gave peptides 
that were unable  to  compete with the immunizing  sequence, 
even when an alternative NH,-terminal isoleucine residue 
0 I W  m 3w 
FREE PEPTIDE li.9 ml) 
FIG. 1. Competitive inhibition ELISA assay using mono- 
clonal antibody CH-3. EIA  microtiter  plates  were  coated  with  the 
ovalbumin-synthetic peptide (IQAENGGC) conjugate used as the 
immunizing  antigen.  Synthetic  peptides used as competing  antigens 
in  the  inhihition  ELISA were: 0, IQAENGGC; 0, IQAENG(@A)C; 0, 
QAENG(BA)C; and +, AENGPHGGC. 
Ac-IQAENG(@A)C; M, IHIQAENGGC; A, HIQAENGGC; V, 
L P l +  
L P l +  
LP2+ CH3 CH3 
1 2  3 4  
- 
FIG. 2. Characterization of monoclonal antibody CH-3. A,  
diagrammatic representation of the NH,-terminal amino acid se- 
quence  (residues 1-30) of human  link  protein,  illustrating (below) the 
cleavage sites of trypsin, chymotrypsin, stromelysin, and elastase, 
and (aboue) the peptide used as the immunogen. Boxed residues 
indicate  the  linker egion of the  synthetic  peptide  antigen. R, samples 
of human  proteoglycan  aggregate  digested  with  proteinases  (10 pg  of 
proteinase/mg of proteoglycan  aggregate,  4 h) were analyzed by SDS- 
PAGE  and  Western  blotting.  Link  protein  components were visual- 
ized using  monoclonal  antibodies  8-A-4 or CH-3 as indicated.  Lane 
I ,  control;  lane 2, chymotrypsin;  lane 3, elastase;  lane 4, trypsin. C, 
human  proteoglycan  aggregate  digested  with  p-aminophenyl  mercuric 
acetate-activated  recombinant  prostromelysin  (10 pg of proteinase/ 
mg of proteoglycan  aggregate, 24 h)  and  then analyzed as in R. 
Nn- h r  19, 23yr 5 8 y r  
born 
6) 
L P 1 - 0  p-" \;:= I - CH3 
Nn. hr lQyr 2% SSrl 
born 
FIG. 3. Changes with age in the CH-3 epitope in human 
articular cartilage. Cartilage proteins from the D3 fraction of 
dissociative CsCl density  gradients were subjected to  SDS-PAGE  and 
Western blotting. Link protein components were visualized using 
monoclonal  antibody  8-A-4 (A)  and monoclonal  antibody  CH-3 (B) .  
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was present (Fig. 1, closed symbols). These results demon- 
strated  the  importance of the free NH2-terminal isoleucine 
residue and  the dependence on  the specific amino acid se- 
quence  adjacent  to  this residue in  the  epitope recognized by 
The specificity of monoclonal antibody CH-3 for human 
LP3(  17) was demonstrated by immunolocalization studies  on 
specific proteinase digestion products of human  articular  car- 
tilage proteoglycan  aggregate (Fig. 2). Following SDS-PAGE 
and electroblotting,  immunolocalization with monoclonal an- 
tibody 8-A-4  (which recognizes internal  epitopes  in  link  pro- 
tein) visualized LP1,  LP2,  and  LP3  in  the undigested prepa- 
ration, with LP1 and LP2 being most abundant and LP3 
being  present  as a minor  component. However, digestion with 
chymotrypsin,  elastase,  or  trypsin  resulted  in  complete  con- 
version of LP1  and  LP2  to  LP3  products,  the sequences of 
which had been determined previously (Fig. 2 A ) .  In  contrast 
to 8-A-4,  monoclonal antibody  CH-3 gave a weak LP3  band 
in  the undigested sample  and  did  not  react  with  the  trypsin 
or elastase digestion products. However, chymotrypsin diges- 
tion, which is known to produce LP3(17), gave a strong 
reaction (Fig. 2B).  Similarly, digestion with  recombinant  stro- 
melysin  produced  a strong  CH-3 reactive band (Fig.  2C). NH2- 
terminal sequencing of this  recombinant  stromelysin-gener- 
ated  LP3 gave the expected  sequence. These  data  demonstrate 
the specificity of antibody  CH-3  for  the sequence NH2- 
IQAENG. . . in  the  native  LP3  preparations. 
Changes with Age in LP3(17) Abundance-In order to eval- 
uate  the  importance of stromelysin  action  in  cartilage  changes 
associated  with aging, the occurrence of CH-3 neoepitope in 
link proteins from human articular cartilage extracts from 
various individuals of different ages was examined (Fig. 3). 
Immunolocalization analysis,  using  antibody 8-A-4, indicated 
that  the relative abundance of LP3 was found  to  increase  with 
age at the expense of the LP1 and LP2 components, in 
agreement with previous results (14). In contrast, however, 
the proportion of LP3(17),  as visualized using the monoclonal 




Results  from several groups indicate  that  the  mechanism 
of proteoglycan catabolism  in  connective  tissues  is complex. 
Protein sequencing studies have documented many of the 
cleavage sites  that  result  from  catabolism of the proteoglycan 
aggregate components, aggrecan (4-6) and link protein (8, 
18). In  recent years, reports  in  the  literature  have focused on 
the metalloproteinases  stromelysin  and collagenase as  being 
the major agents involved in  cartilage proteoglycan degrada- 
tion (28). However, it  is clear that  many of the  proteolytic 
agents responsible  for this  catabolism  still  remain  to  be  iden- 
tified  (4-6,8).  Research  in  our  laboratories  has been directed 
toward using monoclonal antibody technology to identify 
specific in vivo cartilage proteoglycan  breakdown products as 
a means of discriminating between the large number of pro- 
teolytic  agents  that  are  potentially involved in  this process. 
The  present work demonstrates  the feasibility of this  ap- 
proach. Monoclonal antibodies specific for the stromelysin 
cleavage site  in  the degraded  link protein  present  in  catabo- 
lized cartilage proteoglycan aggregate have been produced. 
One of these  antibodies  (CH-3) recognized only the neoepi- 
tope sequence containing an  NH2-terminal isoleucine  (residue 
17 of the  intact  protein)  and  its  adjacent  amino acids but  not 
the  identical sequence present  in  the  undegraded  link  protein. 
This  finding suggests that monoclonal antibody  CH-3  can be 
used to distinguish between the  degradative  action of stro- 
melysin versus other  proteinases  in  matrix  turnover,  since of
the physiologically relevant proteinases studied so far only 
stromelysin cleaves at   this position. Our  studies using  mono- 
clonal  antibody  CH-3  also provided  evidence  suggesting that 
the major proportion of LP3 in the adult is not a final 
degradation  product of stromelysin, even though  during aging 
an  increasing  amount of the  link  protein  in  human  articular 
cartilage is present in the LP3 form. This indicates that 
catabolic agents  other  than  this  metalloproteinase  contribute 
to link  protein  degradation  and  presumably  to  the  turnover 
of matrix molecules in general in  normal  adult cartilage. I t  
still  remains  to be established  whether  or  not multiple pro- 
teolytic agents (including stromelysin) are involved in this 
process. 
These  results  indicate  that neoepitope  monoclonal antibody 
technology is a powerful tool for  identifying the  unique deg- 
radation  products  that  result  from  the  action of individual 
proteolytic agents  in  extracellular  matrix degradation. In  ad- 
dition  to  their  application  in  immunoblotting,  these  reagents 
can also be used for immunohistochemical localization and 
quantitative immunoassay. Thus,  this methodology has  great 
potential for discriminating between the different mecha- 
nisms of cartilage metabolism operating  in  health  and disease. 
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